Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer.
Dong Jin ParkTae Gyun KwonJae Young ParkJae Young JoungHong Koo HaSeong Soo JeonSung-Hoo HongSungchan ParkSeung Hwan LeeJin Seon ChoSung Woo ParkSe Yun KwonJung Ki JoHong Seok ParkSang-Cheol LeeDong Deuk KwonSun Il KimSang Hyun ParkSoo Dong KimChang Wook JeongCheol KwakSeock Hwan Choinull nullPublished in: The world journal of men's health (2024)
ADT+abiraterone/prednisone had lower PSA progression and systemic treatment discontinuation rates than ADT+docetaxel. In conclusion, further studies involving larger, double-blinded randomized trials with extended follow-up periods are necessary.